Effects of BM-573 on Endothelial dependent relaxation and increased blood pressure at early stages of atherosclerosis

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Romero, Miguel ^a,c   Leon Gomez, Elvira ^a   Lobysheva, Irina ^a   Rath, Géraldine ^a   Dogné, Jean Michel ^b   Feron, Olivier ^a   Dessy, Chantal ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF NAMUR   (Belgium)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 573; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MESSENGER RNA; NITRIC OXIDE; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; THROMBOXANE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N-TERBUTYL-N'-(2-(4'-METHYLPHENYLAMINO)-5-NITROBENZENESULFONYL)UREA; NOS3 PROTEIN, MOUSE; REACTIVE OXYGEN METABOLITE; SULFONYLUREA DERIVATIVE; THROMBOXANE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ELEVATED BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; HEART RATE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; VASCULAR ENDOTHELIUM;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; RECEPTORS, THROMBOXANE; SULFONYLUREA COMPOUNDS;

EID: 84962173531     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152579     Document Type: Article

References (47)

1. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109:II27-II33. PMID: 15173060
2. Yang Z, Ming XF. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res. 2006;4:53-65. PMID: 16595793
3. Alp NJ, McAteer MA, Khoo J, Choudhury RP, Channon KM. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. ArteriosclerThromb Vasc Biol. 2004;24:445-450. PMID: 14707037
4. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840-845. PMID: 10952950
5. Reilly MP, Pratico D, Delanty N, Di Minno G, Tremoli E, Rader D, etal. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation. 1998;98:2822-2828. PMID: 9860782
6. Feletou M, Vanhoutte PM, Verbeuren TJ. The thromboxane/endoperoxide receptor (TP): the common villain. J Cardiovasc Pharmacol. 2010;55:317-332. PMID: 20422736
7. Zhang M, Song P, Xu J, Zou MH. Activation of NAD (P) H oxidases by thromboxane A2 receptor uncouples endothelial nitric oxide synthase. ArteriosclerThromb Vasc Biol. 2011;31:125-132. doi: 10.1161/ATVBAHA.110.207712 PMID: 20947827
8. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. ArteriosclerThromb Vasc Biol. 2000;20:1724-1728. PMID: 10894809
9. Dogne JM, Hanson J, Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci. 2005;26:639-644. PMID: 16243403
10. Gendron ME, Thorin E. A change in the redox environment and thromboxane A2 production precede endothelial dysfunction in mice. Am J Physiol Heart Circ Physiol. 2007;293:H2508-H2515. PMID: 17644574
11. Lesault PF, Boyer L, Pelle G, Covali-Noroc A, Rideau D, Akakpo S, et al. Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis. Br J Clin Pharmacol. 2011;71:844-851. doi: 10.1111/j.1365-2125.2010.03858.x PMID: 21564160
12. Dogne JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, etal. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. J Pharmacol ExpTher. 2004;309:498-505. PMID: 14742735
13. Ghuysen A, Lambermont B, Dogne JM, Kolh P, Tchana-Sato V, Morimont P, etal. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism. J Pharmacol ExpTher. 2004;310:964-972. PMID: 15121765
14. Cherdon C, Rolin S, Hanson J, Ooms A, de Leval L, Drion P, etal. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins Other Lipid Mediat. 2011;94:124-132. doi: 10.1016/j.prostaglandins.2011. 03.001 PMID: 21397034
15. Cyrus T, Yao Y, Ding T, Dogne JM, Pratico D. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. Eur J Pharmacol. 2007;561:105-111. PMID: 17306791
16. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva I, Frerart F, etal. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the thirdgeneration beta-blocker nebivolol. Circulation. 2005;112:1198-1205. PMID: 16116070
17. Desjardins F, Lobysheva I, Pelat M, Gallez B, Feron O, Dessy C, etal. Control of blood pressure variability in caveolin-1-deficient mice: role of nitric oxide identified in vivo through spectral analysis. Cardiovasc Res. 2008;79:527-536. doi: 10.1093/cvr/cvn080 PMID: 18349137
18. Romero M, Jimenez R, Sanchez M, Lopez-Sepulveda R, Zarzuelo MJ, O'Valle F, etal. Quercetin inhibits vascular superoxide production induced by endothelin-1: Role of NADPH oxidase, uncoupled eNOS and PKC Atherosclerosis. 2009;202:58-67. doi: 10.1016/j.atherosclerosis.2008.03.007 PMID: 18436224
19. Rouaud F, Romero-Perez M, Wang H, Lobysheva I, Ramassamy B, Henry E, etal. Regulation of NADPH-dependent Nitric Oxide and reactive oxygen species signalling in endothelial and melanoma cells by a photoactive NADPH analogue. Oncotarget. 2014;5:10650-64. PMID: 25296975
20. Romero M, Jiménez R, Hurtado B, Moreno JM, Rodríguez-Gómez I, López-Sepúlveda R, etal. Lack of beneficial metabolic effects of quercetin in adult spontaneously hypertensive rats. Eur J Pharmacol. 2010;627:242-50. doi: 10.1016/j.ejphar.2009.11.006 PMID: 19903466
21. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/-mice in vivo. Circulation. 2003;107:2480-2486. PMID: 12719275
22. Cui W, Matsuno K, Iwata K, Ibi M, Katsuyama M, Kakehi T, etal. NADPH oxidase isoforms and antihypertensive effects of atorvastatin demonstrated in two animal models. J Pharmacol Sci. 2009;111:260-268. PMID: 19881226
23. Jiang F, Guo Y, Salvemini D, Dusting GJ. Superoxide dismutase mimetic M40403 improves endothelial function inapolipoprotein (E)-deficientmice. Br J Pharmacol. 2003;139:1127-1134. PMID: 12871831
24. Kawashima S. Malfunction of vascular control in lifestyle-related diseases: endothelial nitric oxide (NO) synthase/NO system in atherosclerosis. J Pharmacol Sci. 2004;96:411-419. PMID: 15613778
25. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. ArteriosclerThromb Vasc Biol. 2004;24:1006-1014. PMID: 15087308
26. Chen X, Zhang H, McAfee S, Zhang C. The reciprocal relationship between adiponectin and LOX-1 in the regulation of endothelial dysfunction in ApoE knockout mice. Am J Physiol Heart Circ Physiol. 2010;299:H605-H612. doi: 10.1152/ajpheart.01096.2009 PMID: 20581092
27. Raman KG, Gandley RE, Rohland J, Zenati MS, Tzeng E. Early hypercholesterolemia contributes to vasomotor dysfunction and injury associated atherogenesis that can be inhibited by nitric oxide. J Vasc Surg. 2011;53:754-763. doi: 10.1016/j.jvs.2010.09.038 PMID: 21163611
28. Beleznai T, Takano H, Hamill C, Yarova P, Douglas G, Channon K, et al. Enhanced K (+)-channel-mediated endothelium-dependent local and conducted dilation of small mesenteric arteries from ApoE (-/-) mice. Cardiovasc Res. 2011;92:199-208. doi: 10.1093/cvr/cvr181 PMID: 21690174
29. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001;103:1282-1288. PMID: 11238274
30. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, etal. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990;86:228-234. PMID: 2195060
31. Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol. 2003;41:1198-1204. PMID: 12679222
32. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006;291:H985-1002. PMID: 16632549
33. Gelosa P, Ballerio R, Banfi C, Nobili E, Gianella A, Pignieri A, et al. Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin. J Pharmacol ExpTher. 2010;334:199-205. doi: 10.1124/jpet.110.165787 PMID: 20332187
34. Drouin A, Farhat N, Bolduc V, Thorin-Trescases N, Gillis MA, Villeneuve L, etal. Up-regulation of thromboxane A (2) impairs cerebrovascular eNOS function in aging atherosclerotic mice. Pflugers Arch. 2011;462:371-383. doi: 10.1007/s00424-011-0973-y PMID: 21617900
35. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996;93:1107-1113. PMID: 8653830
36. Qian H, Neplioueva V, Shetty GA, Channon KM, George SE. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation. 1999;99:2979-2982. PMID: 10368113
37. Song P, Zhang M, Wang S, Xu J, Choi HC, Zou MH. Thromboxane A2 receptor activates a Rho-associated kinase/LKB1/PTEN pathway to attenuate endothelium insulin signaling. J Biol Chem. 2009;284:17120-17128. doi: 10.1074/jbc. M109.012583 PMID: 19403525
38. Liu CQ, Leung FP, Wong SL, Wong WT, Lau CW, Lu L, etal. Thromboxane prostanoid receptor activation impairs endothelial nitric oxide-dependent vasorelaxations: the role of Rho kinase. Biochem Pharmacol. 2009;78:374-381. doi: 10.1016/j.bcp. 2009.04.022 PMID: 19409373
39. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, etal. p47phoxis required for atherosclerotic lesion progression in ApoE (-/-) mice. J Clin Invest. 2001;108:1513-1522. PMID: 11714743
40. Terashima M, Ohashi Y, Azumi H, Otsui K, Kaneda H, Awano K, et al. Impact of NAD (P) H oxidasederived reactive oxygen species on coronary arterial remodeling: a comparative intravascular ultrasound and histochemical analysis of atherosclerotic lesions. CircCardiovasc Interv. 2009;2:196-204. doi: 10.1161/CIRCINTERVENTIONS.108.799502 PMID: 20031716
41. Feletou M, Huang Y, Vanhoutte PM. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol. 2001;164:894-912.
42. Linton MF, Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. CurrOpin Pharmacol. 2004;4:116-123. PMID: 15063354
43. Wong WT, Tian XY, Huang Y. Endothelial dysfunction in diabetes and hypertension: cross talk in RAS, BMP4, and ROS-dependent COX-2-derived prostanoids. J Cardiovasc Pharmacol. 2013;61:204-214. doi: 10.1097/FJC.0b013e31827fe46e PMID: 23232839
44. Delannoy E, Courtois A, Freund-Michel V, Leblais V, Marthan R, Muller B. Hypoxia-induced hyperreactivity of pulmonary arteries: role of cyclooxygenase-2, isoprostanes, and thromboxane receptors. Cardiovasc Res. 2010;85:582-592. doi: 10.1093/cvr/cvp292 PMID: 19710084
45. Petri MH, Tellier C, Michiels C, Ellertsen I, Dogné JM, Bäck M. Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells. Biochem Biophys ResCommun. 2013;441:393-398. doi: 10.1016/j.bbrc.2013.10.078 PMID: 24161392
46. Arruda RM, Peotta VA, Meyrelles SS, Vasquez EC. Evaluation of vascular function in apolipoprotein E knockout mice with angiotensin-dependent renovascular hypertension. Hypertension. 2005;46:932-936. PMID: 16087779
47. Martinez-Miguel P, Raoch V, Zaragoza C, Valdivielso JM, Rodriguez-Puyol M, Rodriguez-Puyol D, et al. Endothelin-converting enzyme-1 increases in atherosclerotic mice: potential role of oxidized low density lipoproteins. J Lipid Res. 2009;50:364-375. doi: 10.1194/jlr. M800215-JLR200 PMID: 18997155